BH4U's Bio2Skin adhesive is patented and built from biocompatible polymers that bond to skin water through hydrogen bonds, giving strong adhesion with low stripping and no residue. It meets ISO 10993 biocompatibility standards and is bio-based, which lets BH4U pitch both skin health and a reduced environmental footprint.
The platform extends from a base adhesive into bioactive healing, transdermal drug delivery, and sensor-equipped wound monitoring. That breadth lets BH4U sell one adhesive core into dressings, wearables, drug-delivery patches, and remote chronic-wound care.
Source: besthealth4u.pt
BH4U sells into patient care through clinical channels, partnering with patient organisations and hospitals around the world. A patient support program sits alongside its product line to reach people who live with skin-attached medical devices.
The adhesives are positioned for makers and users of wound dressings and wearable devices, while adhesivAI addresses clinicians and patients managing chronic wounds remotely. Messaging centres on MARSI prevention and sustainability to win both clinical and procurement buyers.
Source: besthealth4u.pt
BH4U targets a concrete clinical pain point: medical adhesives that damage skin, causing pain, irritation, and infection risk for patients wearing devices and dressings. Its patented, ISO 10993-compliant Bio2Skin adhesive gives it a platform it can extend into bioactive healing and transdermal drug delivery.
The adhesivAI biosensor patch adds a data and software layer, with machine-learning healing prediction and remote monitoring for chronic wounds. The key questions are regulatory clearance timing and how fast hospital and device-maker partnerships convert into recurring adhesive volume.
Source: besthealth4u.pt
BH4U (BestHealth4U) makes medical adhesives that attach bandages, dressings, and medical devices to skin without the pain, irritation, and infection risk of conventional adhesives. Its line spans Bio2Skin, a biocompatible bio-based adhesive; Bio2Skin Advanced, a bioactive version that speeds skin healing and supports transdermal drug delivery; and adhesivAI, a smart wound patch.
adhesivAI combines a biosensor patch with a companion app that monitors chronic wounds in place and uses machine learning to predict healing. Together the products target Medical Adhesive-Related Skin Injuries (MARSI) for patients who depend on skin-attached devices.
Source: besthealth4u.pt
